These findings demonstrate that targeting the immune checkpoint inhibitory receptor CD200R provides opportunities for the treatment of autoimmune or inflammatory diseases such as AD via different mechanisms than those of currently available therapies. The gene discussed is CD200R1; the disease is Alzheimer disease.